Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

273
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
273
Global Climate Change01:50

Global Climate Change

29.0K
Throughout its ~4.5 billion year history, the Earth has experienced periods of warming and cooling. However, the current drastic increase in global temperatures is well outside of the Earth’s cyclic norms, and evidence for human-caused global climate change is compelling. Paleoclimatology, the study of ancient climate conditions, provides ample evidence for human-caused global climate change by comparing recent conditions with those in the past.
29.0K
Introduction to Global Positioning System01:30

Introduction to Global Positioning System

602
The Global Positioning System (GPS) revolutionized positioning on Earth, providing precise location data through satellite ranging. The GPS system was developed in 1978 by the U.S. Department of Defense  for military use, and it became available for civilian applications in 1983, transforming fields including navigation, fleet management, and time synchronization for telecommunications systems.GPS consists of satellites in medium Earth orbit, about 20,200 kilometers above the surface,...
602
Errors in Global Positioning System01:26

Errors in Global Positioning System

361
Global Positioning System (GPS) technology has revolutionized navigation and positioning, but its accuracy is often compromised by various errors. These errors, stemming from environmental, satellite, and receiver-related factors, require careful mitigation to ensure reliable performance across applications.Atmospheric ErrorsGPS signals travel through the Earth’s ionosphere and troposphere, introducing delays which affect accuracy. The ionosphere is strongly influenced by charged particles,...
361
Global Regulatory Systems01:28

Global Regulatory Systems

694
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
694
Field Application of Global Positioning System01:28

Field Application of Global Positioning System

333
The Global Positioning System (GPS) has become an indispensable tool in fieldwork, offering unparalleled precision and efficiency for surveying, navigation, and infrastructure development. By harnessing signals from a constellation of satellites, GPS receivers determine the location of objects with remarkable speed and accuracy, often completing calculations within a second.Advantages of Modern GPS TechnologyContemporary GPS receivers are designed to meet the practical demands of field...
333

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Daridorexant: First Approval.

Drugs·2022
Same author

Gefapixant: First Approval.

Drugs·2022
Same author

Daridorexant: First Approval.

Drugs·2022
Same author

Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.

Targeted oncology·2022
Same author

Envafolimab: First Approval.

Drugs·2022
Same author

Correction to: Avatrombopag: A Review in Thrombocytopenia.

Drugs·2021
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Related Experiment Video

Updated: Feb 7, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
05:05

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

21.6K

Pegvaliase: First Global Approval.

Anthony Markham1

  • 1Springer, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. bdr@adis.com.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|July 20, 2018
PubMed
Summary
This summary is machine-generated.

Pegvaliase (PALYNZIQ™) effectively reduces blood phenylalanine levels and improves neurological symptoms in adults with phenylketonuria. This enzyme therapy has gained US approval for patients with uncontrolled phenylalanine levels on existing treatments.

More Related Videos

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.6K

Related Experiment Videos

Last Updated: Feb 7, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
05:05

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

Published on: November 4, 2011

21.6K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.6K

Area of Science:

  • Biochemistry
  • Genetics
  • Pharmacology

Background:

  • Phenylketonuria (PKU) is a genetic disorder resulting in neurotoxic phenylalanine accumulation due to phenylalanine hydroxylase deficiency.
  • Current treatments for PKU aim to manage blood phenylalanine levels, but some patients have uncontrolled concentrations.
  • Pegvaliase offers a novel therapeutic approach for managing PKU.

Purpose of the Study:

  • To summarize the development milestones of pegvaliase (PALYNZIQ™).
  • To highlight the clinical trial data leading to the US approval of pegvaliase for phenylketonuria.

Main Methods:

  • Review of clinical trial data, focusing on the phase III PRISM program.
  • Analysis of pegvaliase efficacy in reducing blood phenylalanine levels.
  • Assessment of pegvaliase impact on neurological sequelae in PKU patients.

Main Results:

  • Pegvaliase demonstrated sustained reductions in blood phenylalanine levels.
  • Sustained improvements in neurological sequelae were observed in patients treated with pegvaliase.
  • Positive results from the PRISM trial program supported regulatory submission.

Conclusions:

  • Pegvaliase (PALYNZIQ™) is a significant advancement in PKU treatment.
  • US approval marks a milestone, offering a new option for adults with uncontrolled phenylketonuria.
  • The development of pegvaliase addresses a critical unmet need in managing this genetic disorder.